Figure 1

Representative axial MR images with gadolinium, taken on initial admission. (A) T₁-weighted MR image (T₁WI); (B) Contrast-enhanced T₁WI and (C) T₂-weighted MR image (T₂WI) showing a left occipital tumor with mild contrast enhancing; (D) at one month follow up, T₁WI; (E) contrast-enhanced T₁WI and (F) T₂WI showing no apparent enhanced lesion; (G) 8 months later after the first surgery, T₁WI; (H) contrast-enhanced T₁WI and (I) T₂WI showing marked enhanced mass on the cavity and recurrence; (J) 48 h after the second surgery, T₁WI; (K) contrast-enhanced T₁WI, and (L) T₂WI showing no apparent enhanced lesion; (M) 8 months later after combination radiotherapy and chemotherapy, T₁WI; (N) contrast-enhanced T₁WI and (O) T₂WI showing marked enhanced mass of the wall in the posterior portion of the removal cavity and left temporal areas, and recurrence of the enhanced tumor. (P, Q) 8 months later after combination radiotherapy and chemotherapy, sagittal spinal contrast-enhanced T₁WI after gadolinium infusion showing high-intensity mass lesion in (P) T7, T10, and T12 vertebral bodies (arrowheads) and (Q) T12, L2, L3, L5, and S1 vertebral bodies (arrows).